Clinica BavieraXMAD:CBAV 100 Receivables Turnover is 12.33 as of Mar. 2026. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.41 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 98.52% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Clinica Baviera's Revenue for the
three
months ended in Mar. 2026 was €87.0 Mil. Clinica Baviera's average Accounts Receivable for the
three
months ended in Mar. 2026 was €7.1 Mil.
Hence, Clinica Baviera's Receivables Turnover for the
three
months ended in Mar. 2026 was 12.33.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Clinica Baviera Receivables Turnover Related Terms
Clinica Baviera Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:CBAV vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera (XMAD:CBAV) has a Receivables Turnover of 12.33 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Clinica Baviera and its competitors. According to the industry distribution chart, Clinica Baviera ranks #3 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 1.5%.
Is Clinica Baviera's Receivables Turnover too high?
Clinica Baviera's current Receivables Turnover is 12.33. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. Clinica Baviera's value of 12.33 is 128.8% above this industry median. Based on the distribution chart, Clinica Baviera ranks #3 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #3 out of 203 companies for Receivables Turnover. This places Clinica Baviera in the top 2% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.39. Clinica Baviera's value of 12.33 is 128.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current Receivables Turnover of 12.33 is 128.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current Receivables Turnover is 12.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.41, compared to a current price of €57.40 — trading 38.6% above its estimated fair value. The current Receivables Turnover is 12.33 and 128.8% above the Medical Diagnostics & Research industry median of 5.39. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Receivables Turnover is 12.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €57.40 is trading 38.6% above its estimated GF Value™ of €41.41.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
Receivables Turnover: 12.33
GF Value™: €41.41 vs. price of €57.40 (38.6% above fair value)
Industry Position: 128.8% above the Medical Diagnostics & Research median (#3 of 203)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
